Hutchison China Meditech

OverviewSuggest Edit

Hutchison China MediTech is a biopharmaceutical company, engaging in the research, development, manufacture and sale of pharmaceuticals and healthcare products. It operates through Innovation Platform and Commercial Platform segments. The Company provides drug research and development services and develops, manufactures, distributes, markets and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. It also develops clinical drug candidates, including AZD6094 that is in Phase II clinical trial for treating non-small cell lung, colorectal and gastric cancer; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung and gastric cancer; Sulfatinib, a Phase II clinical trial product for neuroendocrine tumors and thyroid cancers; and Epitinib for the treatment of non-small cell lung cancer that is in Phase Ib clinical trial.

TypePublic
Founded2000
HQCN
Websitechi-med.com

Latest Updates

Employees (est.) (Jul 2021)1,280
Share Price (Sept 2021)$38.4(-1%)
Cybersecurity ratingAMore

Key People/Management at Hutchison China Meditech

Christian Hogg

Christian Hogg

Executive Director and Chief Executive Officer
Johnny Cheng

Johnny Cheng

Executive Director and Chief Financial Officer
Wei-Guo Su

Wei-Guo Su

Executive Director and Chief Scientific Officer
Edith Shih

Edith Shih

Director and Company Secretary
Dan Eldar

Dan Eldar

Non-Executive Director
Zhenping Wu

Zhenping Wu

Senior Vice President, Pharmaceutical Sciences
Show more

Hutchison China Meditech Office Locations

Hutchison China Meditech has an office in Florham Park
Florham Park, NJ, US
25A Vreeland Rd #304
Show all (4)

Hutchison China Meditech Financials and Metrics

Hutchison China Meditech Revenue

Market capitalization (15-Sept-2021)

5.7b

Closing stock price (15-Sept-2021)

38.4
Hutchison China Meditech's current market capitalization is $5.7 b.
Show all financial metrics

Hutchison China Meditech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Hutchison China Meditech Online and Social Media Presence

Embed Graph

Hutchison China Meditech News and Updates

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT

Hutchison China Meditech Blogs

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

— Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for review in June 2021; and MAA validation by the EMA in July 2021 all for advanced neuroendocrine tumors —   Hong Kong, Shanghai & Florham Park, NJ — Monday, September 20, 2021: HUTCHMED (China) Limited (“H…

ESMO2021: An Phase Ib/II Study of Fruquintinib in Combination with Tislelizumab in Patients with Advanced Triple Negative Breast Cancer

Title: An open-label, phase Ib/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple negative breast cancer Lead Author: Debu Tripathy, MD, The University of Texas MD Anderson Cancer Center Session: ePoster Presentation Number:…

Director, Key External Expert (KEE) Liaison

Director, Key External Expert (KEE) Liaison Job Title: Director, Key External Expert (KEE) Liaison Location: Florham Park, NJ   Primary Function The Director, Key External Expert (KEE) Liaison will be part of the HUTCHMED US Commercial organization, supporting the commercial teams across the US to i…

Sr. Brand Director, Colorectal Cancer

Job Title: Sr. Brand Director, Colorectal Cancer Location: Florham Park, NJ   Primary Function As an integral member of the US Marketing Team and the International Product Team, the Sr. Brand Director, Colorectal Cancer, will lead the preparation of one of HUTCHMED’s first product launches in the US…

Director, New Products Marketing

Job Title: Director, New Products Marketing Location: Florham Park, NJ   Primary Function The Director of New Products is an integral member of both the US Marketing Team and the cross-functional International Product Development Team. The New Products Director is responsible for the commercial lead…

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

Hong Kong, Shanghai & Florham Park, NJ — Monday, September 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“B…
Show more

Hutchison China Meditech Frequently Asked Questions

  • When was Hutchison China Meditech founded?

    Hutchison China Meditech was founded in 2000.

  • Who are Hutchison China Meditech key executives?

    Hutchison China Meditech's key executives are Christian Hogg, Johnny Cheng and Wei-Guo Su.

  • How many employees does Hutchison China Meditech have?

    Hutchison China Meditech has 1,280 employees.

  • Who are Hutchison China Meditech competitors?

    Competitors of Hutchison China Meditech include Sygnature Discovery, Moderna and Novartis.

  • Where are Hutchison China Meditech offices?

    Hutchison China Meditech has an office in Florham Park.

  • How many offices does Hutchison China Meditech have?

    Hutchison China Meditech has 4 offices.